The mode of butyrate efficacy is variably defined across studies, including via its capacity as an HDACi [160], especially as HDACi is a general target in cancer treatment [161], as well as via epigenetic regulation by GPR43 activation suppressing methyltransferase-like 3 (METTL3) [154] and cancer regulating miRNAs subsequent to HDACi [160]. The gene discussed is FFAR2; the disease is cancer.